What is Alere's stock symbol?
Alere trades on the New York Stock Exchange (NYSE) under the ticker symbol "ALR."
Where is Alere's stock going? Where will Alere's stock price be in 2017?
6 brokerages have issued 12-month target prices for Alere's stock. Their predictions range from $42.00 to $56.00. On average, they anticipate Alere's stock price to reach $49.50 in the next year.
When will Alere announce their earnings?
Alere is scheduled to release their next quarterly earnings announcement on Friday, November, 4th 2016.
What are analysts saying about Alere stock?
Here are some recent quotes from research analysts about Alere stock:
According to Zacks Investment Research, "Alere Inc., formerly known as Inverness Medical Innovations, Inc., provides products and services, which focus on infectious disease, cardiology, oncology, drugs of abuse and women's health. Alere is headquartered in Waltham, Massachusetts. " (1/9/2017)
Canaccord Genuity analysts commented, "We offer follow-on color after speaking to Alere in some detail in the wake of the company’s receipt of a subpoena from the US Department of Justice (DoJ) related to sales practices in Africa, Asia and Latin America, as well as items related to the US Foreign Corrupt Practices Act (FCPA). Bottom line, we expect the Alere/Abbott deal to be completed sometime by the end of 2016, though not without drama along the way. We reiterate our HOLD and $56 PT despite what we view as at least modest additional risk to the closing of the deal. We think Alere’s 7.7% decline yesterday did bear some sympathy from Valeant’s sharp 51% decline, though we think the ~12% spread between Alere’s closing price and the deal price roughly calibrates the risk at this time. More detail on emerging market revenue. While a significant ~46% of ALR’s revenue base is derived internationally: 1. Alere believes that a portion of a portion" of its emerging market businesses are more likely to be investigated, not the whole of its businesses in Asia Pacific (13% of total revs) and Africa/Latin America (12% of total revs combined). 2. Alere’s position is that hypothetically, if any of its commercial practices are found to have been inappropriate or illegal, that a % of a % of revenues would need to be re- stated, and in that case, would not constitute a material adverse event. 3." (3/16/2016)
Who owns Alere stock?
Alere's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Iridian Asset Management LLC CT (5.70%), Dimensional Fund Advisors LP (3.17%), CNH Partners LLC (2.34%), Alpine Associates Management Inc. (1.46%), Gabelli Funds LLC (1.38%) and Marshall Wace LLP (0.74%). Company insiders that own Alere stock include Carla Flakne, James F Hinrichs, John Bridgen, Mark Gladwell, Melissa Guerdan, Robert Bernard Hargadon and Sanjay Malkani.
Who sold Alere stock? Who is selling Alere stock?
Alere's stock was sold by a variety of institutional investors in the last quarter, including Alpine Associates Management Inc., I.G. Investment Management LTD., Gabelli Funds LLC, Marshall Wace LLP, Gamco Investors INC. ET AL, GABELLI & Co INVESTMENT ADVISERS INC., Iridian Asset Management LLC CT and Dimensional Fund Advisors LP.
Who bought Alere stock? Who is buying Alere stock?
Alere's stock was acquired by a variety of institutional investors in the last quarter, including Prudential PLC, Everett Capital Advisors UK LLP, Mcclain Value Management LLC, Renaissance Technologies LLC, Dumac Inc., Stonepine Capital Management LLC, Gardner Lewis Asset Management L P and Folger Hill Asset Management LP. Company insiders that have bought Alere stock in the last two years include James F Hinrichs and Robert Bernard Hargadon.
How do I buy Alere stock?
Shares of Alere can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Alere stock cost?
One share of Alere stock can currently be purchased for approximately $39.95.